Premium
Alternate dosing regimens of brentuximab vedotin for CD 30+ cutaneous T‐cell lymphoma: reply from the authors
Author(s) -
Stranzenbach R.,
Dippel E.,
Schlaak M.,
Stadler R.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15972
Subject(s) - brentuximab vedotin , dosing , medicine , lymphoma , oncology , cancer research , pharmacology , hodgkin lymphoma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom